Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors

European Journal of Pharmaceutical Sciences

Volumn 8, Issue 4, 1999, Pages 291-299

  Olsson Gisleskog, Per ^a   Hermann, David ^a   Hammarlund Udenaes, Margareta ^b   Karlsson, Mats O ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Benign prostatic hyperplasia; Dutasteride; Finasteride; NONMEM; Population pharmacodynamics; Validation

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SIMULATION; STATISTICAL ANALYSIS;

EID: 0032792436     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(99)00024-X     Document Type: Article

References (8)

1. Beal S.L., Sheiner L.B. NONMEM Users Guide. 1979;University of California, San Fransisco.
2. Johnsson E.N., Karlsson M.O. Xpose - An Splus based model building aid for population analysis with NONMEM. Aarons L., Balant L., Danhof M., Gex-Fabry M., Gundert-Remy U.A., Karlsson M.O., Mentré F., Morselli P.L., Rombout F., Rowland M., Steimer J.-L., Vozeh S. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. 1997;411-413 The European Commission, Brussels.
3. Mentré F., Ebelin M.-E. Validation of population pharmacokinetic/pharmacodynamic analyses: review of proposed approaches. Aarons L., Balant L., Danhof M., Gex-Fabry M., Gundert-Remy U.A., Karlsson M.O., Mentré F., Morselli P.L., Rombout F., Rowland M., Steimer J.-L., Vozeh S. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. 1997;148-160 The European Commission, Brussels.
4. Morris, D.M., Grosse, C.M., Selinger, K.A., 1995. Determination of GI198745 in human serum by LC/APCI/MS. In: Sixth International Symposium for Pharmaceutical and Biomedical Analysis. M-P/A9 (abstract).
5. Olsson Gisleskog P., Hermann D., Hammarlund-Udenaes M., Karlsson M.O. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride. Clin. Pharm. Ther. 64:1998;636-647.
6. Olsson Gisleskog P., Hermann D., Hammarlund-Udenaes M., Karlsson M.O. The pharmacokinetic modeling of GI198745, a compound with parallel linear and non-linear elimination. Br. J. Clin. Pharmacol. 47:1999;53-58.
7. Russell D.W., Wilson J.D. Steroid 5α-reductase: two genes/two enzymes. Annu. Rev. Biochem. 63:1994;25-61.
8. Steiner J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin. Pharmacokinet. 30:1996;16-27.